Diana Cervantes-Madrid

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)–addicted neuroblastomas

Ganesh Umapathy, Jikui Guan, Dan Gustafsson et al. · Science Signaling · 2017 · 51 citations

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Jimmy Van den Eynden, Ganesh Umapathy, Arghavan Ashouri et al. · Science Signaling · 2018 · 39 citations

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Muhammad Wasi Alam, Marcus Borenäs, Dan E. Lind et al. · Frontiers in Oncology · 2019 · 37 citations · Full text

Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids

Diana Cervantes-Madrid, Alfonso Dueñas‐González · Oncology Reports · 2015 · 27 citations · Full text

Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer

Diana Cervantes-Madrid, Guadalupe Domínguez-Gómez, Aurora González‐Fierro et al. · Oncology Letters · 2017 · 27 citations · Full text